{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T20:40:11Z","timestamp":1775853611849,"version":"3.50.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,16]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Coronavirus disease (COVID-19) vaccines have demonstrated excellent efficacy in reducing the morbidity and severity of the disease. However, some patients have been reported to develop systemic rheumatic diseases, such as rheumatoid arthritis, myocarditis, Guillain-Barre syndrome, and giant cell arteritis (GCA) following COVID-19 vaccination. We present a case of GCA with ischaemic optic neuropathy following COVID-19 mRNA vaccination. A 73-year-old woman developed headache, myalgia, scalp tenderness, and jaw claudication 4\u2009days after her seventh dose of the vaccination; she also developed severe visual disturbances 1\u2009month after the vaccination. The blood examination tests showed an increased serum C-reactive protein level and erythrocyte sedimentation rate. The echogram for the temporal artery showed a halo sign. Ophthalmic examination revealed ischaemic optic neuropathy in both eyes. The patient was treated with a high-dose glucocorticoid and tocilizumab under the diagnosis of GCA with ischaemic optic neuropathy, obtaining mild improvement of the symptoms. This report underscores the need for clinical vigilance and further data collection regarding GCA cases after COVID-19 vaccination.<\/jats:p>","DOI":"10.1093\/mrcr\/rxae042","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T19:23:24Z","timestamp":1722713004000},"page":"131-136","source":"Crossref","is-referenced-by-count":3,"title":["New onset of giant cell arteritis with ischaemic optic neuropathy following the seventh dose of COVID-19 mRNA vaccination: A case report and literature review"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8651-4149","authenticated-orcid":false,"given":"Shin-ichiro","family":"Ohmura","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Seirei Hamamatsu General Hospital , Hamamatsu, Shizuoka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruka","family":"Yonezawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Seirei Hamamatsu General Hospital , Hamamatsu, Shizuoka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshitaka","family":"Yukishima","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Seirei Hamamatsu General Hospital , Hamamatsu, Shizuoka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Gohto","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Seirei Hamamatsu General Hospital , Hamamatsu, Shizuoka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Obana","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Seirei Hamamatsu General Hospital , Hamamatsu, Shizuoka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,8,3]]},"reference":[{"key":"2025011615465178000_R1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"2025011615465178000_R2","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/imm.13443","article-title":"New-onset autoimmune phenomena post-COVID-19 vaccination","volume":"165","author":"Chen","year":"2022","journal-title":"Immunology"},{"key":"2025011615465178000_R3","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.2169\/internalmedicine.0257-22","article-title":"New-onset seropositive rheumatoid arthritis following COVID-19 vaccination in a patient with seronegative status","volume":"61","author":"Yonezawa","year":"2022","journal-title":"Intern Med"},{"key":"2025011615465178000_R4","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.kint.2021.09.009","article-title":"New-onset systemic lupus erythematosus beginning as class V lupus nephritis after COVID-19 vaccination","volume":"100","author":"Zavala-Miranda","year":"2021","journal-title":"Kidney Int"},{"key":"2025011615465178000_R5","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/mrcr\/rxac085","article-title":"Possible case of polyarteritis nodosa with epididymitis following COVID-19 vaccination: a case report and review of the literature","volume":"7","author":"Ohkubo","year":"2023","journal-title":"Mod Rheumatol Case Rep"},{"key":"2025011615465178000_R6","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/rheumatology\/keab756","article-title":"Risk of giant cell arteritis and polymyalgia rheumatica following COVID-19 vaccination: a global pharmacovigilance study","volume":"61","author":"Mettler","year":"2022","journal-title":"Rheumatology"},{"key":"2025011615465178000_R7","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1136\/ard-2022-223480","article-title":"2022 American College of Rheumatology\/EULAR classification criteria for giant cell arteritis","volume":"81","author":"Ponte","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025011615465178000_R8","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"2025011615465178000_R9","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108628","article-title":"MDA5 governs the innate immune response to SARS-CoV-2 in lung epithelial cells","volume":"34","author":"Yin","year":"2021","journal-title":"Cell Rep"},{"key":"2025011615465178000_R10","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103479","article-title":"The mRNA-LNP platform\u2019s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory","volume":"24","author":"Ndeupen","year":"2021","journal-title":"iScience"},{"key":"2025011615465178000_R11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/mrcr\/rxad043","article-title":"New-onset severe eosinophilic granulomatosis with polyangiitis following the third dose of mRNA COVID-19 vaccine: a case report","volume":"8","author":"Mahdi","year":"2023","journal-title":"Mod Rheumatol Case Rep"},{"key":"2025011615465178000_R12","first-page":"2143","article-title":"Inflammatory rheumatic diseases developed after COVID-19 vaccination: presentation of a case series and review of the literature","volume":"27","author":"Akkuzu","year":"2023","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2025011615465178000_R13","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000033948","article-title":"Development of giant cell arteritis after vaccination against SARS-CoV2: a case report and literature review","volume":"102","author":"Wakabayashi","year":"2023","journal-title":"Medicine"},{"key":"2025011615465178000_R14","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/qjmed\/hcac171","article-title":"Giant cell arteritis presenting with chronic cough and headache after BNT162b2 mRNA COVID-19 vaccination","volume":"115","author":"Ishizuka","year":"2022","journal-title":"QJM"},{"key":"2025011615465178000_R15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/0961203311430222","article-title":"Giant cell arteritis and polymyalgia rheumatica after influenza vaccination: report of 10 cases and review of the literature","volume":"21","author":"Soriano","year":"2012","journal-title":"Lupus"},{"key":"2025011615465178000_R16","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102732","article-title":"Giant cell arteritis or polymyalgia rheumatica after influenza vaccination: a study of 12 patients and a literature review","volume":"20","author":"Liozon","year":"2021","journal-title":"Autoimmun Rev"},{"key":"2025011615465178000_R17","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1097\/WNO.0000000000000947","article-title":"Granuloma annulare, scalp necrosis, and ischemic optic neuropathy from giant cell arteritis after Varicella-Zoster virus vaccination","volume":"41","author":"Nichani","year":"2021","journal-title":"J Neuroophthalmol"},{"key":"2025011615465178000_R18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jns.2017.01.053","article-title":"Giant cell arteritis following varicella zoster vaccination","volume":"375","author":"Lotan","year":"2017","journal-title":"J Neurol Sci"},{"key":"2025011615465178000_R19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cei\/uxad033","article-title":"Autoimmune\/inflammatory syndrome induced by adjuvants (ASIA): past, present, and future implications","volume":"213","author":"Seida","year":"2023","journal-title":"Clin Exp Immunol"},{"key":"2025011615465178000_R20","article-title":"Increased incidence of giant cell arteritis after introduction of a live Varicella Zoster virus vaccine","volume":"8","author":"Agger","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2025011615465178000_R21","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e17899","article-title":"Incidence of giant cell arteritis is associated with COVID-19 prevalence: a population-level retrospective study","volume":"9","author":"Mulhearn","year":"2023","journal-title":"Heliyon"},{"key":"2025011615465178000_R22","article-title":"Coronavirus Pandemic (COVID-19)","volume-title":"Published online at OurWorldInData.org","author":"Mathieu","year":"2020"},{"key":"2025011615465178000_R23","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.ophtha.2016.05.008","article-title":"Evaluating the incidence of arteritic ischemic optic neuropathy and other causes of vision loss from giant cell arteritis","volume":"123","author":"Chen","year":"2016","journal-title":"Ophthalmology"},{"key":"2025011615465178000_R24","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0002-9394(99)80192-5","article-title":"Ocular manifestations of giant cell arteritis","volume":"125","author":"Hayreh","year":"1998","journal-title":"Am J Ophthalmol"},{"key":"2025011615465178000_R25","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.survophthal.2005.06.011","article-title":"Giant cell (temporal) arteritis: an overview and update","volume":"50","author":"Rahman","year":"2005","journal-title":"Surv Ophthalmol"},{"key":"2025011615465178000_R26","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1212\/WNL.38.3.352","article-title":"Neurologic disease in biopsy-proven giant cell (temporal) arteritis","volume":"38","author":"Caselli","year":"1988","journal-title":"Neurology"},{"key":"2025011615465178000_R27","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1136\/bmj.282.6260.269","article-title":"Prognosis in giant-cell arteritis","volume":"282","author":"Graham","year":"1981","journal-title":"Br Med J Clin Res Ed"},{"key":"2025011615465178000_R28","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/art.1780370705","article-title":"Giant cell arteritis in Iceland. An epidemiologic and histopathologic analysis","volume":"37","author":"Baldursson","year":"1994","journal-title":"Arthritis Rheum"},{"key":"2025011615465178000_R29","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/1529-0131(199801)41:1<26::AID-ART4>3.0.CO;2-0","article-title":"Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis","volume":"41","author":"Cid","year":"1998","journal-title":"Arthritis Rheum"},{"key":"2025011615465178000_R30","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0161-6420(93)31608-8","article-title":"Visual prognosis in giant cell arteritis","volume":"100","author":"Aiello","year":"1993","journal-title":"Ophthalmology"},{"key":"2025011615465178000_R31","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/rheumatology\/36.2.251","article-title":"Clinical features in patients with permanent visual loss due to biopsy-proven giant cell arteritis","volume":"36","author":"Font","year":"1997","journal-title":"Br J Rheumatol"},{"key":"2025011615465178000_R32","first-page":"e107","article-title":"Bilateral ischemic optic neuropathy from giant cell arteritis following COVID-19 vaccination","volume":"43","author":"Che","year":"2023","journal-title":"J Neuro Ophthalmol"},{"key":"2025011615465178000_R33","article-title":"A case of giant cell arteritis with a normal erythrocyte sedimentation rate (ESR) post ChAdOx1 nCoV-19 vaccination","volume":"14","author":"Xia","year":"2022","journal-title":"Cureus"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxae042\/58869250\/rxae042.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/1\/131\/58869250\/rxae042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/1\/131\/58869250\/rxae042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T15:53:35Z","timestamp":1737042815000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/9\/1\/131\/7726895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,3]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,8,3]]},"published-print":{"date-parts":[[2025,1,16]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxae042","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,8,3]]}}}